MARKET

CAPR

CAPR

Capricor Therapeutics Inc
NASDAQ
30.50
-2.92
-8.74%
After Hours: 30.45 -0.05 -0.16% 19:36 03/13 EDT
OPEN
33.00
PREV CLOSE
33.42
HIGH
33.00
LOW
29.41
VOLUME
2.61M
TURNOVER
--
52 WEEK HIGH
40.37
52 WEEK LOW
4.300
MARKET CAP
1.58B
P/E (TTM)
-16.9586
1D
5D
1M
3M
1Y
5Y
1D
Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative
Simply Wall St · 11h ago
Capricor Therapeutics Nears Key Milestones After Earnings Call
TipRanks · 12h ago
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel
Seeking Alpha · 16h ago
Capricor selloff today a buying opportunity, says Roth Capital
TipRanks · 18h ago
Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss
Dow Jones · 18h ago
Capricor Therapeutics Price Target Raised to $63.00/Share From $50.00 by B. Riley Securities
Dow Jones · 18h ago
Capricor Therapeutics Is Maintained at Buy by B. Riley Securities
Dow Jones · 18h ago
B. Riley Securities Maintains Buy on Capricor Therapeutics, Raises Price Target to $63
Benzinga · 19h ago
More
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

Webull offers Capricor Therapeutics Inc stock information, including NASDAQ: CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.